← Back to Home

How Does Breast Tumor Stiffness Dampen Immune Alarms? Study Points to Pin1 Protein

The stiffened environment around tumors may silence immune alarms inside cancer cells through Pin1. Cell and animal experiments show that disrupting this mechanism can improve responses to immunotherapy, but whether this translates into benefits for patients still requires clinical validation.

By SURL BioNews

Whether cancer cells can be recognized by the immune system may also depend on how stiff the surrounding tissue is. A breast cancer study found that a stiff extracellular matrix suppresses genetic activity that could otherwise trigger an immune response inside cancer cells through the Pin1 protein. This offers another potential avenue for drug intervention linking the tumor’s physical environment to immune evasion.

The study was published on October 28 in *Cancer Discovery*, coordinated by Giannino Del Sal, with Rebecca Bertolio as first author and support from Fondazione AIRC. The team combined human cell cultures, experimental animals, and analyses of patient samples and clinical data. Evidence on whether disrupting Pin1 can improve treatment responses came primarily from preclinical models.

The study focused on the cell nucleus. When the extracellular matrix becomes stiffer, Pin1 becomes more stable and accumulates in cancer cell nuclei. It maintains interactions between HP1α and nuclear lamins, helping preserve the compact structure of heterochromatin and the integrity of the nuclear envelope, while keeping some transposable elements suppressed. Once reactivated, these genomic sequences may trigger cellular immune alarms.

After removing Pin1, the team observed heterochromatin loosening, reactivation of transposable elements such as LINE1, and activation of cGAS/STING and type I interferon signaling. This alarm system responds to abnormal DNA appearing in the cytoplasm. The study also found that reducing Pin1 can promote the production of neoantigens derived from transposable elements, giving cancer cells more features that the immune system can recognize.

These changes were further reflected in treatment experiments: in breast cancer models with fibrosis and low immune activity, genetically removing Pin1 or inhibiting its activity with drugs increased tumor sensitivity to immune checkpoint blockade. This type of immunotherapy helps the immune system attack tumors by relieving inhibition of T cells.

According to ANSA’s reporting on the same study, the team combined ATRA, ATO, and immunotherapy in preclinical experiments and improved control of tumor growth without adding conventional chemotherapy. However, these remain findings from experimental models and cannot establish that patients can omit chemotherapy or that this combination has demonstrated clinical efficacy in breast cancer.

The study also proposed another use that requires validation: using Pin1 as a biomarker to predict treatment responses. However, analyses of patient samples and treatment efficacy in animals are not yet sufficient to establish a basis for clinical treatment selection. Which patients might benefit, how safe the combination treatment is, and whether Pin1 can reliably predict responses all require dedicated human studies.

References

  1. International Centre for Genetic Engineering and Biotechnology
  2. ANSA
  3. Life Science Network (PubMed-imported article abstract)